Chronic Rhinitis Solution NEUROMARK Secures €62.5 Million as Irish Startup Neurent Medical Closes Series C

Why It Matters

The capital fast‑tracks deployment of a clinically validated, minimally invasive therapy for a condition affecting millions, highlighting strong market demand for innovative ENT solutions.

Key Takeaways

• €62.5M Series C led by MVM, Sofinnova.
• NEUROMARK treats chronic rhinitis via impedance‑controlled RF.
• Funding fuels EU commercial expansion and new indications.
• Board adds MVM and Sofinnova partners.
• Highlights growing MedTech investment in Europe.

Pulse Analysis

Chronic rhinitis impacts a sizable global patient base, yet treatment options remain limited to pharmacotherapy and surgery, both of which carry compliance or safety concerns. NEUROMARK’s proprietary impedance‑controlled radiofrequency technology offers a targeted, minimally invasive approach that disrupts overactive posterior nasal nerves, delivering durable symptom relief with minimal downtime. Early clinical data suggest a favorable safety profile, positioning the device as a potential new standard of care for ENT specialists seeking to address the root cause rather than merely managing symptoms.

The €62.5 million Series C injection, spearheaded by MVM Partners and Sofinnova, signals robust investor confidence in Neurent’s commercial strategy and technology differentiation. In a funding climate where European MedTech startups typically raise between €5 million and €20 million, Neurent’s raise sits at the high end, reflecting both the market size of chronic rhinitis and the perceived scalability of its platform. The capital will fund regulatory submissions, expand sales infrastructure across key European markets, and generate additional real‑world evidence to strengthen reimbursement pathways.

Looking ahead, Neurent aims to leverage its impedance‑control platform beyond chronic rhinitis, exploring adjacent indications in sinonasal inflammation and potentially other peripheral nerve disorders. The addition of MVM and Sofinnova partners to the board brings strategic guidance and deep industry networks, accelerating partnership opportunities and future fundraising. As MedTech investors increasingly prioritize devices with clear clinical outcomes and scalable business models, Neurent’s trajectory may set a benchmark for Irish and broader European health‑tech ventures seeking to translate innovative engineering into measurable patient benefit.